Rytary is an oral medication used to treat Parkinson's disease symptoms. It is available in several dosage strengths.
What are the available Rytary doses?
Rytary capsules come in three different strengths: 47.5 mg of carbidopa and 12.5 mg of levodopa, 95 mg of carbidopa and 23.75 mg of levodopa, and 142.5 mg of carbidopa and 35.6 mg of levodopa [1].
How is Rytary administered and dosed?
The usual starting dose for Rytary is one capsule taken three times a day. This dosage is typically administered every four to six hours while awake. The dosage may be adjusted based on individual patient response and tolerability [1].
When does Rytary patent exclusivity expire?
According to DrugPatentWatch.com, Rytary's primary patent is set to expire in 2027. However, there may be other patents that extend exclusivity for the drug [2].
Can generic versions of Rytary be available after patent expiry?
Following the expiration of patents, generic versions of Rytary could become available. The exact timeline for generic market entry depends on regulatory approvals and potential patent challenges [2].
What is Rytary used for?
Rytary is indicated for the treatment of Parkinson's disease symptoms, including those that occur earlier in the disease and motor fluctuations that may happen later on [1].